X4 Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview
X4 Pharmaceuticals Inc XFOR.OQ XFOR.O is expected to show a rise in quarterly revenue when it reports results on November 13 for the period ending September 30 2024
The Boston Massachusetts-based company is expected to report revenue of $1.694 million, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for X4 Pharmaceuticals Inc is for a loss of 17 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $5.00, above its last closing price of $0.62.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | 0.13 | 0.01 | -0.07 | Missed | -1,325.9 |
Mar. 31 2024 | -0.15 | -0.16 | -0.26 | Missed | -59.6 |
Dec. 31 2023 | -0.17 | -0.15 | -0.10 | Beat | 34.6 |
Sep. 30 2023 | -0.15 | -0.15 | -0.01 | Beat | 93.3 |
Jun. 30 2023 | -0.16 | -0.16 | -0.33 | Missed | -102 |
Mar. 31 2023 | -0.21 | -0.22 | -0.16 | Beat | 26.3 |
Jan. 1 0001 | -0.21 | -0.24 | -0.29 | Missed | -20.2 |
Sep. 30 2022 | -0.31 | -0.30 | -0.26 | Beat | 13.1 |
This summary was machine generated November 11 at 15:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。
熱議股票
沒有相關數據